Improvements in eliciting dose across baseline sensitivities following 12 months of epicutaneous immunotherapy (EPIT) in peanut-allergic children aged 4 to 11 years
J Allergy Clin Immunol Pract
.
2020 Oct;8(9):3219-3221.
doi: 10.1016/j.jaip.2020.05.030.
Epub 2020 Jun 2.
Authors
Matthew Greenhawt
1
,
Edwin H Kim
2
,
Dianne E Campbell
3
,
Todd D Green
4
,
Romain Lambert
5
,
David M Fleischer
6
Affiliations
1
Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, Colo.
2
University of North Carolina School of Medicine, Chapel Hill, N.C.
3
DBV Technologies SA, Montrouge, France; Children's Hospital at Westmead, Sydney, Australia.
4
DBV Technologies SA, Montrouge, France; UPMC Children's Hospital of Pittsburgh and University of Pittsburgh School of Medicine, Pittsburgh, Pa.
5
DBV Technologies SA, Montrouge, France.
6
Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, Colo. Electronic address: David.Fleischer@childrenscolorado.org.
PMID:
32502548
DOI:
10.1016/j.jaip.2020.05.030
No abstract available
Publication types
Research Support, U.S. Gov't, P.H.S.
MeSH terms
Allergens
Arachis*
Child
Child, Preschool
Desensitization, Immunologic
Humans
Immunotherapy
Peanut Hypersensitivity* / therapy
Substances
Allergens
Grants and funding
K08 HS024599/HS/AHRQ HHS/United States